^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MammaPrint®

    Company:
    Agendia
    Related tests:
    3d
    Advances in Breast Cancer Diagnostics: From Screening to Precision Medicine. (PubMed, Diagnostics (Basel))
    Precision diagnostics now encompass next-generation sequencing (NGS)-based comprehensive genomic profiling, enabling identification of actionable alterations such as PIK3CA mutations, HER2 amplification, BRCA1/2 pathogenic variants, and NTRK fusions, each linked to approved therapeutic agents. The purpose of this review is to provide a comprehensive synthesis of current and emerging diagnostic modalities in breast cancer-from population-level screening to individualized molecular profiling-and to examine how integrative, multimodal diagnostic platforms are reshaping clinical decision-making in the era of precision medicine.
    Review • Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 amplification • PIK3CA mutation • HER-2 amplification + HR-positive • NTRK fusion
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    6d
    Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Legacy Health System | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MammaPrint® • BluePrint
    7d
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer (clinicaltrials.gov)
    P2, N=94, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib)
    7d
    LESS: Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (clinicaltrials.gov)
    P2, N=696, Recruiting, UNICANCER | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    7d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Orserdu (elacestrant)
    16d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group | N=1050 --> 1520
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • Orserdu (elacestrant)
    18d
    Multigene assays in early breast cancer: Current evidence, limits and future directions. (PubMed, Cancer Treat Rev)
    The evolution of genomic assays, including Oncotype DX®, MammaPrint®, Prosigna®, EndoPredict®, and Breast Cancer Index®, along with the collaboration of multidisciplinary teams, signifies a transition toward more customized and effective therapeutic strategies. Our work offers a thorough overview of the advancing strategies in breast cancer management in terms of multigene assay application to the clinical routine, specifically focusing on current evidence, limits and future research directions.
    Review • Journal
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • Breast Cancer Index® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    22d
    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov)
    P3, N=1670, Recruiting, NRG Oncology | Trial primary completion date: Apr 2026 --> Apr 2031
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • exemestane
    23d
    Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P3, N=446, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • PGR positive
    |
    MammaPrint®
    |
    Kisqali (ribociclib)
    27d
    Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer Outcomes. (PubMed, JCO Precis Oncol)
    Despite AA women exhibiting a higher proportion of high-risk MP scores, survival outcomes were comparable with those of White women. These findings underscore MP's consistent prognostic performance across racial groups but further highlight the need to address additional clinical and social determinants influencing breast cancer outcomes beyond genomic risk alone.
    Retrospective data • Journal
    |
    MammaPrint®
    1m
    Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Legacy Health System
    New P2 trial
    |
    MammaPrint® • BluePrint
    1m
    Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Nov 2026
    Trial completion date
    |
    MammaPrint®
    |
    carboplatin • albumin-bound paclitaxel